For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Gemfibrozil - Lipid modification
PAD Profile : Gemfibrozil - Lipid modification
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Atorvastatin
- Rosuvastatin calcium
- Simvastatin
- Ezetimibe
- Pravastatin sodium
- Fluvastatin sodium
- Evolocumab
- Alirocumab
- Fenofibrate
- Bezafibrate
- Ciprofibrate
- Colesevelam hydrochloride
- Colestyramine
- Bempedoic acid
- Inclisiran
- Icosapent
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
The PCN recommends the use of fibrates for lipid modification as follows:
Familial hypercholesterolaemia - as per NICE CG71 (updated July 2016) in patients with familial hypercholesterolaemia (FH) with intolerance or contraindications to statins or ezetimibe. Patients should be offered a referral to a specialist with expertise in FH for consideration for treatment with either a bile acid sequestrant (resin), nicotinic acid or a fibrate to reduce their LDL-C concentration. For these patients, fibrates should be considered BLUE (no information sheet) on the traffic light system. Specialists to initiate treatment or make a recommendation for the primary care prescriber to initiate treatment.
Hypertriglyceridaemia - as a treatment option for patients with hypertriglyceridaemia (>10mmol/L).
BLUE traffic light status - Specialists to initiate treatment or make a recommendation for the primary care prescriber to initiate treatment.
Policy statements and further information below.